The Inflammatory Bowel Disease (IBD) market refers to the products, external modalities, methods, strategies, service and treatments that targets IBD majorly including Crohn and Colitis and Ulcerative Colitis. IBD is a long-standing inflammatory disease of unknown cause that involves the gastrointestinal tract in a relapsing and remitting pattern. It extends to drugs and substances used in the treatment of severe diseases and includes therapeutic interventions such as drugs, biologics aimed at managing symptoms, achieving remission or enhancing patient’s quality of life once affected by such diseases. Given the increasing prevalence of IBD in population, caused by genetic factors, environmental conditions and lifestyle, the market has a great potential for development.

Influenza diagnostics refers to the methods and techniques used to detect and identify the presence of influenza viruses in clinical samples collected from patients suspected of having influenza infection. These diagnostics include various laboratory tests such as rapid antigen tests, molecular tests (like PCR), and viral cultures. The goal of influenza diagnostics is to accurately and quickly identify the influenza virus strain present to guide patient management, treatment decisions, and public health interventions, especially during flu seasons or outbreaks.

Inhalable Drugs Market Size Was Valued at USD 34.5 Billion in 2023, and is Projected to Reach USD 60.3 Billion by 2032, Growing at a CAGR of 6.6% From 2024-2032.